Market Cap 2.91B
Revenue (ttm) 528.30M
Net Income (ttm) -56.11M
EPS (ttm) N/A
PE Ratio 233.00
Forward PE 93.20
Profit Margin -10.62%
Debt to Equity Ratio 1.70
Volume 2,746,600
Avg Vol 5,225,684
Day's Range N/A - N/A
Shares Out 308.53M
Stochastic %K 75%
Beta 0.66
Analysts Strong Sell
Price Target $15.64

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 662 2000
Fax: 609 662 2001
Address:
47 Hulfish Street, Princeton, United States
ididathing9999
ididathing9999 Nov. 14 at 4:18 PM
$FOLD omg 5 cents away from being flat YTD!!!
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 5:11 AM
$FOLD is currently trading at $9.38, near its 60D high of $9.64, indicating a bullish sentiment but also a potential resistance level. The RSI at 69.61 suggests that the stock is approaching overbought territory, which may lead to a pullback. The MA30 at $8.64 and MA50 at $8.42 provide support levels that reinforce a bullish trend, as the price is above both moving averages. Given the current market context, the directional bias leans slightly bullish, but caution is warranted due to the high RSI. Suggested entry is at $9.20, allowing for a slight pullback. Set a stop loss at $8.90 to manage risk effectively. For profit targets, aim for $9.60 (near the 60D high) and $10.00 as a secondary target, which aligns with psychological resistance levels. Monitor price action closely, especially around the resistance level. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:18 AM
$FOLD: The last close at $9.32 indicates the stock is currently near the upper end of its 60-day range ($7.28 - $9.64). The RSI of 70.37 suggests that the stock is overbought, which may lead to a pullback. The 30-day moving average (MA30) at $8.55 and the 50-day moving average (MA50) at $8.36 indicate a bullish trend, but the high RSI raises caution for potential short-term weakness. Directional bias: Bearish in the short term due to overbought conditions, but bullish long-term based on moving averages. Suggested entry: Consider entering a short position around $9.30. Stop: Place a stop at $9.65 to limit potential losses. Targets: First target at $8.80 (near MA30), second target at $8.55 (MA30 support). Monitor for signs of reversal or strength before making further trades. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:53 AM
$FOLD: The last close at $9.32 indicates the stock is currently near the upper end of its 60-day range ($7.28 - $9.64). The RSI of 70.37 suggests that the stock is overbought, which may lead to a pullback. The 30-day moving average (MA30) at $8.55 and the 50-day moving average (MA50) at $8.36 indicate a bullish trend, but the high RSI raises caution for potential short-term weakness. Directional bias: Bearish in the short term due to overbought conditions, but bullish long-term based on moving averages. Suggested entry: Consider entering a short position around $9.30. Stop: Place a stop at $9.65 to limit potential losses. Targets: First target at $8.80 (near MA30), second target at $8.55 (MA30 support). Monitor for signs of reversal or strength before making further trades. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:14 PM
$FOLD 2 yr trial on DMX200; so 3rd major rev pillar ~ 2029, imho
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:10 PM
$FOLD product is: DMX200
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:09 PM
$FOLD paid $30M to a partner for FSGS rare kidney mkt…40,000 in US alone. Good compliment to their core solns. Not sure what tge rev split is, but it appears $FOLD has exclusive, at leadt in US
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:05 PM
$FOLD expecting patent/royalty wins with 3 companies in the next couple yrs
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:04 PM
$FOLD moving mfgr site from China to Ireland. 2028 probable 100% move.
0 · Reply
ms1sd
ms1sd Nov. 10 at 7:56 PM
$FOLD good info from the conference interview, live on this app, rt now
0 · Reply
Latest News on FOLD
Amicus Therapeutics: Moving Towards Consistent Profitability

Nov 11, 2025, 4:56 PM EST - 3 days ago

Amicus Therapeutics: Moving Towards Consistent Profitability


3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 6 weeks ago

3 Of My Favorite Biotech Stocks Under $10

DVAX MRNA NUVB PFE


Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Jun 12, 2025, 10:14 AM EDT - 5 months ago

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma


3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 10 months ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI


ididathing9999
ididathing9999 Nov. 14 at 4:18 PM
$FOLD omg 5 cents away from being flat YTD!!!
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 5:11 AM
$FOLD is currently trading at $9.38, near its 60D high of $9.64, indicating a bullish sentiment but also a potential resistance level. The RSI at 69.61 suggests that the stock is approaching overbought territory, which may lead to a pullback. The MA30 at $8.64 and MA50 at $8.42 provide support levels that reinforce a bullish trend, as the price is above both moving averages. Given the current market context, the directional bias leans slightly bullish, but caution is warranted due to the high RSI. Suggested entry is at $9.20, allowing for a slight pullback. Set a stop loss at $8.90 to manage risk effectively. For profit targets, aim for $9.60 (near the 60D high) and $10.00 as a secondary target, which aligns with psychological resistance levels. Monitor price action closely, especially around the resistance level. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:18 AM
$FOLD: The last close at $9.32 indicates the stock is currently near the upper end of its 60-day range ($7.28 - $9.64). The RSI of 70.37 suggests that the stock is overbought, which may lead to a pullback. The 30-day moving average (MA30) at $8.55 and the 50-day moving average (MA50) at $8.36 indicate a bullish trend, but the high RSI raises caution for potential short-term weakness. Directional bias: Bearish in the short term due to overbought conditions, but bullish long-term based on moving averages. Suggested entry: Consider entering a short position around $9.30. Stop: Place a stop at $9.65 to limit potential losses. Targets: First target at $8.80 (near MA30), second target at $8.55 (MA30 support). Monitor for signs of reversal or strength before making further trades. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:53 AM
$FOLD: The last close at $9.32 indicates the stock is currently near the upper end of its 60-day range ($7.28 - $9.64). The RSI of 70.37 suggests that the stock is overbought, which may lead to a pullback. The 30-day moving average (MA30) at $8.55 and the 50-day moving average (MA50) at $8.36 indicate a bullish trend, but the high RSI raises caution for potential short-term weakness. Directional bias: Bearish in the short term due to overbought conditions, but bullish long-term based on moving averages. Suggested entry: Consider entering a short position around $9.30. Stop: Place a stop at $9.65 to limit potential losses. Targets: First target at $8.80 (near MA30), second target at $8.55 (MA30 support). Monitor for signs of reversal or strength before making further trades. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:14 PM
$FOLD 2 yr trial on DMX200; so 3rd major rev pillar ~ 2029, imho
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:10 PM
$FOLD product is: DMX200
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:09 PM
$FOLD paid $30M to a partner for FSGS rare kidney mkt…40,000 in US alone. Good compliment to their core solns. Not sure what tge rev split is, but it appears $FOLD has exclusive, at leadt in US
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:05 PM
$FOLD expecting patent/royalty wins with 3 companies in the next couple yrs
0 · Reply
ms1sd
ms1sd Nov. 10 at 8:04 PM
$FOLD moving mfgr site from China to Ireland. 2028 probable 100% move.
0 · Reply
ms1sd
ms1sd Nov. 10 at 7:56 PM
$FOLD good info from the conference interview, live on this app, rt now
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 9:18 PM
JP Morgan has adjusted their stance on Amicus Therapeutics ( $FOLD ), setting the rating to Overweight with a target price of 18 → 19.
0 · Reply
Hognose
Hognose Nov. 6 at 5:14 PM
$PFE $CPRX $FOLD $EXAS $ABVX underpriced bio. Get it.
0 · Reply
All4Retiring
All4Retiring Nov. 6 at 12:56 PM
0 · Reply
kempo
kempo Nov. 6 at 12:35 PM
$FOLD sell it already…. 20$ pps
0 · Reply
erevnon
erevnon Nov. 5 at 6:50 PM
Goldman Sachs maintains Amicus Therapeutics $FOLD at Neutral and raises the price target from $9 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 5:37 PM
$FOLD just delivered a clean earnings beat 💥 Galafold and Pombiliti + Opfolda sales climbed strong, pushing revenues up 19% year over year — a solid sign of growing momentum. Full breakdown of Amicus’ Q3 numbers here 👉 https://www.zacks.com/stock/news/2785814/amicus-q3-earnings-beat-higher-product-sales-drive-yy-revenues?cid=sm-stocktwits-2-2785814-teaser-19675&ADID=SYND_STOCKTWITS_TWEET_2_2785814_TEASER_19675
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 4:50 PM
Goldman Sachs has adjusted their stance on Amicus Therapeutics ( $FOLD ), setting the rating to Neutral with a target price of 9 → 11.
0 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 4:37 PM
$FOLD beats Q3 expectations — but what's driving this biotech play? 🚀 📈 EPS of 17 cents vs. 12-cent estimate; revenue up 19% year over year on a reported basis 💊 Strong sales from Galafold & new Pombiliti + Opfolda 🔎 Ongoing studies to expand Fabry and Pompe disease labels Discover what's fueling Amicus' growth and future prospects 👉 https://www.zacks.com/stock/news/2785814/amicus-q3-earnings-beat-higher-product-sales-drive-yy-revenues?cid=sm-stocktwits-2-2785814-body-19617&ADID=SYND_STOCKTWITS_TWEET_2_2785814_BODY_19617
0 · Reply
Hognose
Hognose Nov. 5 at 7:10 AM
$FOLD expect upgrades to come in.
0 · Reply
Viking0919
Viking0919 Nov. 4 at 10:55 PM
0 · Reply
AEBullbunny
AEBullbunny Nov. 4 at 8:02 PM
$FOLD institutional liquidity is stacking up in the order books. ⬆️
0 · Reply
AEBullbunny
AEBullbunny Nov. 4 at 7:27 PM
$FOLD That was institutional absorption at 9ish twice. She’s hit bottom and going for 10.
0 · Reply